Table 2.
Prostate SBRT prospective cohorts.
| Author | No. of Patients | Dose/No. of Fractions(#) | bPFS * | Early Toxicity (≥Grade2) | Late Toxicity (≥Grade 2) |
|---|---|---|---|---|---|
| Bolzicco et al. 2013 [47] | 100 | 35 Gy/5# | 94.4% at 3 years | GU 12%, GI 18% | GU 3%, GI 1% |
| Meier et al. 2016 [48] | 309 | 36.25–40 Gy/5# | 97.1% at 5 years | GU 26%, GI 2.8% | GU 14%, GI 2% |
| Loblaw et al. 2017 [49] | 114 | 35–40 Gy/5# | 97.3% at 5 years | Not reported | Not reported |
| Helou et al. 2017 [50] | 259 | 35–40 Gy/5# | Not reported | Not reported | GU 34%, GI 14% |
| Fuller et al. 2017 [51] | 259 | 38 Gy/4# | 100% at 5 years | Not reported | GU 13.7%, GI 4.5% |
* biochemical progression-free survival.